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Edited by Gerrit van MeerAbstract Multidrug resistance protein (MRP) 1 belongs to the
‘C’ branch of the ABC transporter superfamily. MRP1 is a high-
aﬃnity transporter of the cysteinyl leukotriene C4 and is respon-
sible for the systemic release of this cytokine in response to an
inﬂammatory stimulus. However, the substrate speciﬁcity of
MRP1 is extremely broad and includes many organic anion con-
jugates of structurally unrelated endo- and xenobiotics. In addi-
tion, MRP1 transports unmodiﬁed hydrophobic compounds, such
as natural product type chemotherapeutic agents and mutagens,
such as aﬂatoxin B1. Transport of several of these compounds
has been shown to be dependent on the presence of reduced glu-
tathione (GSH). More recently, GSH has also been shown to
stimulate the transport of some conjugated compounds, including
sulfates and glucuronides. Here, we summarize current knowl-
edge of the substrate speciﬁcity and modes of transport of
MRP1 and discuss how the protein may recognize its structur-
ally diverse substrates.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Multidrug resistance1. Introduction
Multidrug resistance protein 1 (MRP1/ABCC1) was identi-
ﬁed in 1992 as the cause of multidrug resistance in an anthra-
cycline selected human small cell lung carcinoma cell line,
H69AR [1]. The drug resistance proﬁle of H69AR cells in-
cludes several classes of natural product cytotoxic agents, as
well as certain heavy metal oxyanions [2–4]. An intriguing fea-
ture of the H69AR cells was their collateral sensitivity to theAbbreviations: BSO, buthionine sulfoximine; LTC4, leukotriene C4;
MRP1, multidrug resistance protein 1; P-gp, P-glycoprotein; CFTR,
cystic ﬁbrosis transmembrane conductance regulator; E217bG, estra-
diol-17b-D-glucuronide; GSH, glutathione; NBD, nucleotide-binding
domain; MSD, membrane spanning domain; SUR, sulfonylurea rec-
eptor; MALDI TOF, matrix-assisted laser desorption/ionization time
of ﬂight; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; TM,
transmembrane
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(BSO) as a consequence of an unexplained 6-fold decrease in
cellular GSH levels relative to parental H69 cells [5]. The
cross-resistance of H69AR cells to natural products such as
Vinca alkaloids and epipodophyllotoxins, as well as anthracy-
clines, suggested the possible involvement of P-glycoprotein
(P-gp/ABCB1), which at the time was the only known human
multidrug transporter [6]. However, resistance was not modu-
lated by agents that reversed P-gp-mediated resistance, and no
increase in P-gp levels could be detected [2,7,8]. In contrast, the
MRP1 gene was extensively ampliﬁed in H69AR cells and
MRP1 mRNA levels were elevated approximately 100-fold
[1]. The marked increase in levels of MRP1 mRNA relative
to the parental H69 cells facilitated the cloning of MRP1
cDNA by diﬀerential hybridization. Sequencing of MRP1 re-
vealed it to be an ABC transporter, but only very distantly re-
lated to P-gp. Its closest known human relative at the time was
the cystic ﬁbrosis transmembrane conductance regulator
(CFTR/ABCC7). Despite the lack of amino acid sequence
identity with P-gp (approximately 19% overall), gene transfec-
tion experiments conﬁrmed the ability of MRP1 to confer
resistance to a number of natural product drugs, as well as
arsenical and antimonial oxyanions, consistent with the estab-
lished phenotype of H69AR cells [9,10]. It is now known that
MRP1 is a member of a family of nine, possibly ten, proteins
in humans, the members of which have been characterized
functionally to varying extents, as described elsewhere in this
issue. The MRPs (ABCC1–6, 10–12), together with the ATP-
gated chloride channel, CFTR (ABCC7), and the ATP-depen-
dent sulfonylurea receptors (SURs) (ABCC8 and ABCC9),
which are potassium channel regulators, comprise the ‘C’
branch of the ABC superfamily [11].
Clinical studies have documented the expression of MRP1 in
a range of solid and haematological cancers and, in some
cases, have correlated MRP1 expression with negative re-
sponse to treatment and disease outcome. These studies have
been reviewed extensively elsewhere [12–15]. In this minire-
view, we summarize current knowledge of the substrate speci-
ﬁcity and modes of transport of MRP1 and discuss how the
protein may recognize its diverse substrates (see Table 1).2. Substrate speciﬁcity of MRP1
The convergence of several unrelated lines of investigation
contributed to the early identiﬁcation of a large number ofblished by Elsevier B.V. All rights reserved.
Table 1
Substances transported by MRP1 (ABCC1)
Compound Class Examples
Drugs/Xenobiotics
Antineoplastics Folate-based antimetabolites
(methotrexate, edatrexate, ZD1694),
anthracyclines (doxorubicin,
daunorubicin, epirubicin, idarubicin),
plant alkaloids (etoposide, vincristine,
vinblastine, paclitaxel, irinotecan, SN-38),
antiandrogens (ﬂutamide,
hydroxyﬂutamide)
Antivirals Saquinavir, ritonavir
Antibiotics Diﬂoxacin, grepaﬂoxacin
Metalloids Sodium arsenite, sodium arsenate,
potassium antimonite, potassium
antimony tartrate
Fluorescent probes Calcein, Fluo-3, BCECF, SNARF
Toxicants Aﬂatoxin B1, methoxychlor, fenitrothion,
chlorpropham
Drug/Xenobiotic conjugates
GSH conjugates 2,4-Dinitrophenyl-SG, bimane-SG,
N-ethylmaleimide-SG, doxorubicin-SG,
thiotepa-SG, cyclophosphamide-SG,
melphalan-SG, chlorambucil-SG,
ethacrynic acid-SG, metolachlor-SG,
atrazine-SG, sulforaphane-SG, aﬂatoxin
B1-epoxide-SG, 4-nitroquinoline
1-oxide-SG, As(SG)3
Glucuronide conjugates Etoposide-Gluc, 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol (NNAL)-3b-O-
Gluc, SN-38-gluc, 4-methylumbelliferyl-
b-D-gluc, 6-hydroxy-5,7-dimethyl-2-
methylamino-4-(3-pyridylmethyl)
benzothiazole sulfate (E3040S)-Gluc
Naturally occurring metabolites
GSH conjugates Leukotriene C4, prostaglandin A2-SG,
15-deoxy-D12,14 prostaglandin J2-SG,
hydroxynonenal-SG
Glucuronide conjugates 17b-Estradiol-17-b-D-gluc,
glucuronosylbilirubin, bis-
lucuronosylbilirubin, hyodeoxycholate-6-
a-Gluc
Sulfate conjugates Estrone 3-sulfate,
dehydroepiandrosterone sulfate,
sulfatolithocholate
Folates Folic acid, L-leucovorin
Peptides GSH, GSSG
Other Bilirubin
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many of these putative substrates has now been conﬁrmed
by in vitro transport studies using membrane vesicles from
MRP1 transfected cells. One contributing factor was the prior
characterization of the drug resistance proﬁle of H69AR cells
from which MRP1 was cloned [2–4,7]. However, another fac-
tor stemmed from the suspicion that MRP1 was the protein
defective in naturally occurring strains of mutant (TR and
Esai) rats [16,17]. Both mutant strains are characterized by a
biliary transport deﬁcit, similar to that seen in the rare human
inherited disorder, Dubin–Johnson Syndrome [18]. By analyz-
ing the bile composition of the mutant rats and their ability/
inability to secrete a wide variety of compounds into bile, a
great deal of information had been acquired concerning the
substrate speciﬁcity of the transporter(s) involved. Biochemical
studies had also identiﬁed a conjugated organic anion trans-
porter in the plasma membrane of mast cells and eosinophilswith functional characteristics similar to that of the hepato-
canalicular transporter defective in the TR and Esai rats
[19]. In fact, the transport defect in these rats and in Dubin–
Johnson Syndrome involves MRP2 (ABCC2) whereas the
transporter in mast cells and eosinophils is MRP1. Neverthe-
less, because the substrate speciﬁcities of the two proteins over-
lap extensively, the information from both lines of
investigation was extremely useful in the early characterization
of the substrate proﬁles of MRP1 and subsequently, MRP2.
The ﬁrst MRP1 substrate identiﬁed by vesicle transport
studies was the conjugated cysteinyl leukotriene C4 (LTC4),
which was a known substrate of the conjugated organic anion
transporter in mast cells [20–23] (Fig. 1). Mouse knock-out
studies have conﬁrmed that this inﬂammatory cytokine is in-
deed a physiological substrate of MRP1 [24]. The protein
has also been shown to be capable of ATP-dependent trans-
port of anionic glutathione, glucuronide and sulfate conjugates
of an extremely diverse array of endo- and xenobiotics (re-
viewed in [13,25,26]). The structural diversity of some exam-
ples of the better characterized MRP1 substrates is
illustrated in Fig. 1. The aﬃnity of MRP1 for some of its sub-
strates is relatively high for such a promiscuous transporter.
For example, the Km values for LTC4 and the GS-conjugate
of aﬂatoxin B1 epoxide are 100–200 nM [22,27]. The protein
can also display surprising structural speciﬁcity. For example,
17b and 16a glucuronides of estriol diﬀer by more than 20-fold
in their ability to competitively inhibit LTC4 transport [28].
One of the general observations to emerge from vesicular
transport studies of MRP1 is that structurally unrelated com-
pounds with diﬀerent anionic substituents, which may be sub-
strates or simply able to bind to the protein without being
transported, often act as competitive inhibitors of transport
of well-characterized substrates such as LTC4 and estradiol-
17b-D-glucuronide (E217bG) [22,28]. The studies also show
that the rank order of potency of inhibition is substrate depen-
dent, prompting the suggestion that the substrates and ‘inhib-
itors’ establish distinct but overlapping sets of contacts with a
common binding pocket on the protein [22,29].3. Modes of MRP1-mediated transport
Although gene transfer experiments conﬁrmed that MRP1
could enhance the eﬄux of several natural product drugs, initial
attempts with membrane vesicle preparations to demonstrate
that the protein was a direct, ATP-dependent drug transporter
were unsuccessful [22]. Several observations using drug resis-
tant cell lines overexpressing MRP1 suggested that cellular
GSH levels inﬂuenced the ability of the transporter to eﬄux
at least some of the drugs to which it conferred resistance.
GSH depletion with BSO diminished eﬄux of certain drugs,
while the relatively non-speciﬁc organic anion transport inhib-
itor, probenecid, both decreased GSH release and increased
drug accumulation [30–32]. Overall, these observations sug-
gested that MRP1 may mediate the eﬄux of both GSH and
drugs, and that these processes might in some way be coupled.
Fig. 1 illustrates the structures of some GSH-dependent MRP1
substrates. Vesicular transport studies conﬁrmed that transport
of certain unmodiﬁed drugs, such as vincristine, and xenobiot-
ics such as aﬂatoxin B1, is GSH-dependent [22,27,33]. Both
inhibition studies and determination of kinetic parameters of
transport indicated that GSH markedly increased the aﬃnity
Fig. 1. Structures of some compounds that bind and/or are transported by MRP1 in a GSH-dependent or independent manner. The ﬁgure illustrates
the structures of a number of MRP1 substrates, including molecules (leukotriene C4 and GS-aﬂatoxin B1-endo-epoxide) that are transported with
relatively low Km values (100–200 nM) [20,22,27], as well as examples of conjugated and unconjugated substrates that are transported in a GSH-
dependent manner. LY475776 is a tricyclic isoxazole that is a GSH-dependent inhibitor of MRP1 that inhibits LTC4 transport with an IC50 of
60–70 nM [67]. AFB1, aﬂatoxin B1; GSSG, oxidized glutathione.
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clear that the presence of drug increases the aﬃnity of MRP1
for GSH [33]. Initially, it was thought that the positive cooper-
ativity observed between transport of GSH and a second
substrate might be a mechanism that was restricted to unconju-
gated compounds. However, there are now several examples of
sulfate, glucuronide and glutathione conjugates that display
GSH-dependent or stimulated transport [34–38]. It is also
apparent that at least in some cases, such as estrone sulfate
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)-
glucuronide, GSH transport is not stimulated, despite the fact
that the presence of GSH both decreases the Km and increases
the Vmax for the second substrate [35,36]. Conversely, a number
of compounds have been identiﬁed, notably certain bioﬂavo-
noids and verapamil derivatives, that markedly stimulate
GSH transport by both decreasing its Km and increasing its
Vmax, apparently without being transported themselves [39–
41]. The stimulatory eﬀect of GSH can also be obtained with
a variety of GSH analogs including non-sulfur containing trip-
eptides, such as ophthalmic acid [26,41] or short chain alkyl
derivatives, such as S-methyl GSH, which is actually more
eﬀective than GSH in enhancing transport of estrone sulfate
but less eﬀective than GSH in stimulating vincristine transport
[33,35,36]. The eﬀect of GSH and its derivatives on the trans-
port of a second substrate can be very large. However, it may
be an extreme example of a more general mechanism. Several
examples of ‘cooperativity’ between two substrates or a sub-
strate and another ligand, other than GSH, have been docu-
mented for MRP1 and other related proteins such as MRP2
[42,43].A conceptual framework that may be applicable to the inter-
action of ABC drug transporters with more than one substrate
or ligand is provided by studies of soluble multidrug binding
proteins, such as QacR from Staphylococcus aureus. QacR is
a drug-dependent transcription factor rather than a drug trans-
porter. However, like a multidrug resistance protein such as
P-gp, QacR binds structurally diverse hydrophobic cations
[44]. The protein has also been crystallized in the presence of
various ligands [44]. QacR has a large and ﬂexible binding
pocket that is exceptionally rich in aromatic and polar amino
acids, as well as critical glutamate residues involved in ionic
interactions with the protein’s cationic substrates. The binding
pocket can be viewed as containing multiple mini-pockets for
individual drugs that overlap to various extents. The pocket
can also undergo substantial changes in shape and volume
upon interaction with a ligand. This ﬂexibility allows the simul-
taneous accommodation of more than one compound, despite
the fact that in some cases these compounds may form binary
complexes with the protein in which their binding sites would
be predicted to overlap [45]. Thus the binding of one compound
eﬀectively creates an alternative binding site for another. In
principle, this site could have a higher or lower aﬃnity for
the second compound than occupied by that ligand in a binary
complex. However, if it has a higher aﬃnity then positive coop-
erativity would be expected. In this type of model, the binding
could be ordered or random. In the former case, only one sub-
strate may be aﬀected, as observed with the eﬀect of GSH on
MRP1-mediated transport of estrone sulfate and NNAL-glu-
curonide [35,36], while in the latter the interaction with both
substrates may be altered, as observed with the combination
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drug transporters indicate that substrate binding results in con-
formational changes in the protein, the possibility cannot be ex-
cluded that the binding of one substrate may mask residues that
disfavor binding of the second compound, or the compound it-
self may contribute directly to the creation of a second binding
site, without an alteration in protein conformation. At least
with respect to GSH binding to MRP1, however, the evidence
that the tripeptide induces conformational changes in the trans-
porter is quite strong [46,47]. To what extent this may inﬂuence
the substrate speciﬁcity and transport activity of the protein
under physiological conditions is not known.4. Substrate recognition by MRP1
Unlike many ABC proteins, MRP1 contains three rather
than two membrane spanning domains (MSDs) (Fig. 2)
[1,48–50]. The additional MSD (MSD0) of MRP1 has beenFig. 2. Cartoons of the predicted topology and transmembrane helix packing
the MSDs MRP1 based on experimental evidence, secondary structure predic
[61]. Transmembrane helices (TMs) known to contain amino acid residues tha
motifs in the nucleotide binding domains (NBDs) are indicated by: A (Walker
regions of the protein is consistent between upper and lower panels. The low
MSD1 (grey) and MSD2 (blue) of MRP1 based on the crystal structure of the
of TM helices in MSD0 (pink) is presently completely unknown, as is the mshown experimentally to contain ﬁve transmembrane (TM)
helices, while the two core MSDs (MSD1 and MSD2) have a
more typical ABC structure, each containing 6 TM helices
and an intracellular COOH-terminus connected to a nucleo-
tide-binding domain (NBD). Thus, this NH2-terminus of
MRP1 is glycosylated and extracellular [49]. Several other
ABCC proteins contain a third NH2-terminal MSD with
similar predicted topologies. These include MRPs 2, 3, 6 and
7 and the two SURs. Partial deletions of MSD0 in MRP1
and mutation of certain amino acids in this domain interfere
with protein processing and activity [51–53]. However, it ap-
pears likely that they do so by interfering with correct folding
of the remainder of the protein, since MSD0 can be removed in
its entirety (amino acids 1–203) and the truncated protein
retains the ability to traﬃc to its normal, basolateral location
in the plasma membrane. The MSD0-less protein can also
transport a number of substrates [54–58]. Although not essen-
tial for traﬃcking to the plasma membrane or transport activ-
ity, MSD0 is required for eﬃcient retention of MRP1 at theof MRP1. The upper panel is a schematic of the predicted topology of
tion algorithms, such as HMMTOP, and molecular dynamics modeling
t inﬂuence substrate speciﬁcity are marked with an asterisk. Conserved
A), B (Walker B) and ‘C’ (the ABC signature). The coloring of various
er panel shows a cartoon of the predicted packing of the TM helices of
bacterial lipid transporter MsbA [100–102] (see text). The arrangement
anner in which it interacts with the remainder of the protein.
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minally truncated forms of MRP1 that are retained in the
endoplasmic reticulum following elimination of traﬃcking
signals located at the COOH-terminal end of the protein
[59,60]. Thus MSD0 and the COOH-terminal region of
MRP1 contain at least partially redundant elements that con-
tribute to the processing and traﬃcking of the protein [60].
Nevertheless, the demonstration that MRP1 retains transport
activity in the absence of MSD0 indicates that the major deter-
minants of substrate binding and translocation are located in
the core region of the protein. As described below, this region
of the protein has been extensively mutated resulting in a topo-
logical ‘map’ of amino acids that are involved in determining
substrate speciﬁcity, as well as the overall activity of the pro-
tein. More recently, energy minimized models of MSD1 and
MSD2 of MRP1 have been developed [61]. The model pro-
vides the opportunity to integrate functional data from the
mutational studies with a possible three-dimensional structure
of the substrate translocation pathway. It has also provided a
framework for further mutational and/or cross-linking studies
designed to test its validity.
The mapping of regions and individual amino acids involved
in substrate binding and transport by MRP1 has relied exten-
sively on site-directed mutagenesis and UV-crosslinking studies
with photoactivateable substrates and other ligands. Photola-
beling studies have been carried out with unmodiﬁed LTC4
[22,56] and an arylazido LTC4 derivative [62], azido-GSH
derivatives [63,64], compounds that bind to the protein in a
GSH-dependent manner (e.g. azidoagosterol-A) [55,65] and
the tricyclic isoxazole LY475776 [63,67,68] and others that bind
independently but are less speciﬁc for MRP1 (e.g. iodoaryl
azido derivatives of the quinoline, N-(hydrocinchonidin-
8 0-yl)-4-azido-2-hydroxybenzamide (IACI) and rhodamine
123 (IAARh123) [69,70]). Co-expression studies with various
fragments of MRP1, partial proteolysis and, most recently,
MALDI TOF mass spectrometry of complete proteolytic di-
gests have been used to localize regions of the protein to which
these various ligands are cross-linked [71]. In general, the major
sites of cross-linking detected by co-expression and partial pro-
teolysis studies appear to involve, at the very least, regions
spanning TMs 10 and 11 in MSD1 and TMs 16 and 17 in
MSD2. However, the distribution of labeling diﬀers depending
on the type of photoactivateable agent used.
LTC4 and azidophenacyl-GSH predominantly label MSD1,
while GSH-dependent compounds such as Agosterol A and
LY475776 primarily label MSD2, and compounds such as
IACI and IAARh123 label sites in both MSDs to more or less
equivalent extents. Recent MALDI TOF mass spectrometry
studies of MRP1 labeled with LTC4 have identiﬁed TM6
and TM7, as well as TM10 and TM17 as sites of cross-linking
[71]. These studies also detected labeling of the COOH-proxi-
mal region of the cytoplasmic linker connecting MSD0 and
MSD1 which appears contrary to previous reports using co-
expressed fragments of MRP1 labeled with either LTC4 or
azidophenacyl-GSH [57]. However, weak labeling of the
MSD0–MSD1 linker was observed with 125I-labeled aryl-azido
GSH [64]. There has also been a report of the photolabeling of
MSD0 itself by an azido-derivative of LTC4 [62]. Regardless of
the reason for diﬀerences in photolabeling results, the region
of the MSD0–MSD1 linker between amino acids 204–280
has been shown to be essential for substrate binding, transport
activity and traﬃcking of MRP1 [54,57,56,65,72]. The diﬀer-ences in labeling proﬁle between GSH-dependent ligands, such
as Agosterol A and LY475776 that predominantly label
MSD2, and the preferential labeling of MSD1, as opposed
to the MSD0–MSD1 linker, by LTC4 and azidophenacyl-
GSH, suggest that regions of MSD1 may be of critical impor-
tance for binding of the GS-moiety of these compounds. Site-
directed mutagenesis studies summarized below support this
suggestion.
Mutagenesis studies of MRP1 have conﬁrmed the impor-
tance of residues in TMs 10, 11, 16 and 17 in determining sub-
strate speciﬁcity and overall activity [29,61,66,73–80]. They
have also revealed the contribution of residues in other TM
helices (TMs 6, 7, 8, 9, 12, 14, and 15) [52,53,73–75,81–86]
and cytoplasmic loops [75,87,88], such as that connecting
TMs 15 and 16, in deﬁning the substrate speciﬁcity of the pro-
tein. In some cases, mutagenesis has been guided by functional
diﬀerences observed between highly conserved mammalian
orthologs of MRP1 [79,84,89–94] and in others, by structural
diﬀerences between MRP1 and its human homologs with over-
lapping substrate speciﬁcity, such as MRP2 and MRP3
[95–98]. In addition, amino acids with side chains expected to
contribute to substrate recognition and interhelical interaction
(e.g. polar, ionizable and aromatic residues), or to a-helical
geometry (e.g. Pro) and positioning within the membrane
(e.g. aromatic and basic residues) have been extensively
mutated.
These studies have also revealed that major diﬀerences in
substrate speciﬁcity between MRP1 orthologs can be attribut-
able to changes in a single amino acid. For example, despite
the fact that human MRP1 was cloned from an anthracycline
selected cell line, several highly conserved non-primate mam-
malian orthologs do not confer resistance to this class of drugs
[89,91–93]. Those that have been tested are also poor trans-
porters of some steroid conjugates which are transported rel-
atively well by human MRP1. In mouse and rat Mrp1, these
diﬀerences can be largely eliminated simply by conversion of
a Gln residue in TM14 and an Ala residue in TM17 to Glu
and Thr, respectively, which are the corresponding amino
acids in human MRP1 [79,84,92]. It is also apparent that
the relationship between conservation of function and struc-
ture among homologs is complex and impossible to predict
from amino acid sequence alone, as shown by mutational
studies of TM17 of human MRP1, MRP2 and MRP3.
TM17 is the most highly conserved TM among these homo-
logs. Between MRP1 and MRP3 the helix diﬀers in only
two residues. However, it is clear from mutation of polar res-
idues in TM17 of all three proteins that comparable conserved
residues establish diﬀerent interactions with common sub-
strates [29,96–98]. For example, with respect to the transport
of E217bG by MRP1 and MRP3 there is little overlap be-
tween the residues involved. In MRP1, all residues shown to
aﬀect interaction with E217bG are located in the predicted in-
ner leaﬂet region of the helix. In contrast, in MRP3 several
critical amino acids are in the predicted outer leaﬂet region
of the helix and mutations of the corresponding amino acids
in MRP1 have no eﬀect on transport of this common sub-
strate.
Mutations in TM17 of MRP1 aﬀect drug resistance proﬁles
and transport of a number of anionic and conjugated sub-
strates, but none have been found that selectively alter LTC4
transport. The lack of speciﬁc interaction of residues in TM17
with LTC4 is supported by the observation that replacement
Fig. 3. Putative aromatic ‘basket’ close to the cytoplasmic end of the
translocation pathway of MRP1 predicted by atomic homology
models of the second and third MSDs of the transporter. The ﬁgure
was generated using PyMol and is based on the molecular dynamics
models of MSD1 and MSD2 of MRP1 [61]. A lateral view in the plane
of the membrane is shown with TM helices 10, 11, 16 and 17 shown as
ribbons. Trp553 TM10, Trp1198 TM16, and Trp1246 TM17 are shown as
yellow spheres. Tyr1243 TM17 and Phe594 TM11 are shown in pink and
red, respectively. The predicted positions of membrane interfaces are
indicated by the orange lines.
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dicted membrane-cytosol interface with Ala residues has little
eﬀect on LTC4 transport [99]. However, mutation of Arg
1249
does abrogate LTC4 binding and overall activity of the trans-
porter [80]. In TM16, the presence of a Glu residue at position
1204 is critical for eﬃcient transport of GSH and LTC4 but not
several other substrates [80]. However, to date this is the only
mutation in these two helices that has been shown to selectively
aﬀect transport of GSH and the GSH conjugated leukotriene.
Overall, these results and those from recent mass spectrometry
studies [71] are consistent with the suggestion raised by cross-
linking studies that the major determinants of binding of these
compounds are in MSD1.
Mutational analysis of TM11 has identiﬁed Asn590, Arg593,
Phe594 and Pro595 (all located in predicted TM11) as being
important for LTC4 binding [61,74–76]. However, alanine sub-
stitution of Asn590 aﬀects transport of a variety of substrates,
apparently by reducing the binding of ATP by NBD1 [76],
although other amino acid substitutions have no eﬀect. On
the other hand, while alanine substitution of Phe594 eliminates
LTC4 binding and overall transport activity, conservative
mutations have diﬀerential eﬀects on substrate speciﬁcity sug-
gesting that this residue may interact directly with substrate
[61]. Although photolabeling studies have implicated the
region encompassing TMs10 and 11 as the major site of
cross-linking of GSH-derivatives and conjugates, no addi-
tional polar, aromatic or ionizable residues in these TMs have
been identiﬁed that selectively aﬀect the transport of LTC4.
Thus it appears highly likely that other regions are critical
for the speciﬁc recognition of GSH, LTC4 and possibly other
GS-conjugates. TM6 is a probable candidate [71,74,81]. It is
relatively rich in charged residues, mutation of which aﬀects
either overall activity (as exempliﬁed by Asp336), or selectively
decreases transport of LTC4 and GSH (as exempliﬁed by
Lys332 and His335) [74,81]. In addition, Bao et al. [99] replaced
amino acids 320-337 (corresponding to TM6) with alanine and
demonstrated that unlike TM17, TM6 is critical for the bind-
ing and transport of LTC4. Finally, mass spectrometry analy-
ses also indicate that TM6 is part of the LTC4 binding site of
MRP1 [71].
Another of the more intriguing observations to emerge from
mutational studies of MRP1 concerns the role of aromatic
amino acids in substrate recognition. A number of studies indi-
cate that aromatic amino acids in the inner leaﬂet regions of
helices in MSD1 and MSD2 are involved in recognition of spe-
ciﬁc substrates [29,73]. However, recent models derived using
molecular dynamics simulations of MSD1 and MDS2 of
MRP1 indicate that they may also play a more general role
in deﬁning a ‘gateway’ to the translocation pathway [61].
The models are based on the crystal structures of the bacterial
lipid transporter MsbA from V. cholera and E. coli, and an
E. coliMsbA based homology model of P-gp that incorporates
data from cysteine cross-linking studies [100–102]. The models
indicate that Trp553 (TM10), Trp1198 (TM16), Tyr1243 and
Trp1246 (TM17) that are known to aﬀect substrate speciﬁcity
and/or overall activity [29,73,77] could form an aromatic
‘basket’ located close to the cytosolic interface of a possible
translocation pathway that would be completed by Phe594 in
TM11 (Fig. 3). The results of mutational studies are consistent
with this suggestion [61].
Aromatic amino acids are extremely important in the initial
interaction of substrates with soluble multidrug binding pro-teins. For example, in QacR, initial interaction with a substrate
such as rhodamine 123 displaces two Tyr residues, which in the
absence of drug are buried in the drug-binding pocket. This
displacement then results in conformational changes that shift
the protein from its DNA- to drug-bound form [44]. If this pre-
dicted feature of MRP1 is correct, it raises the interesting pos-
sibility that interactions between these residues and substrate
play a pivotal role in transducing conformational changes
resulting from initial substrate binding to other regions of
the protein.
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